louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04838093: COVID-19 Testing in Patients With Vascular Disorders
Official title: COVID-19 Testing in Patients With Vascular Disorders - a Prospective Cohort Study at a Tertiary Care Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2021-04-08
Enrollment: 2243
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We investigated clinical data from all patients presenting at the hospital with vascular disorders, including peripheral artery disease (PAD), cardiac disorders (CD), aortic aneurysm (AA), extracranial artery disorders (EAD) and venous disorders (VD).

Brief summary: Background: To investigate the prevalence of SARS-CoV-2 infection in hospitalized patients with vascular disorders after implementing institutional and governmental safety measures.

Materials and Methods: Vascular patients (VPs) admitted to our tertiary care hospital were routinely tested for SARS-CoV-2 infection on a two days basis between March and December, 2020. The prevalence of SARS-CoV-2 was compared between VPs and two independent Austrian populations (April and November 2020) tested by the Austrian Ministry of Science. The results were also compared to a cohort of health care personnel (HCP) working in close proximity to the study patients, tested weekly, between March and December, 2020. RT-PCR and antigen test were used to detect SARS-CoV-2.


Eligibility criteria: Inclusion Criteria:

All inpatient admissions

Exclusion Criteria:

Outpatient admissions

Primary outcomes:
measure: prevalence of SARS-CoV-2 infection
timeFrame: March 16 to December 07, 2020
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
affiliation: Wolf.eilenberg@meduniwien.ac.at
name: Wolf W Eilenberg, MD. PhD.
role: STUDY_CHAIR
References:
Clinical trial NCT05484193: GnRH Agonist for Luteal Phase Support.
Official title: Comparison of Pregnancy Rates After Luteal Phase Support With GnRH Agonist Versus Progesterone - a Prospective Randomized Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Use of GnRH Agonist Alone for Luteal Phase Support in Fresh IVF Cycles
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2022-08-02
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective To assess the the efficacy of luteal support with GnRH agonist in patients undergoing IVF in antagonist-based hcg triggered cycles compared with standard luteal support with progesterone.

Design prospective randomized controled study Subjects Patients who underwent antagonist-based cycles performed in the "Shaare Zedek Medical Center" IVF clinic between 2020 and 2022 Intervention Intranasal GnRH-agonist or vaginal Progesterone for luteal support.

Main outcome measures Pregnancy and clinical pregnancy rates, ohss.

The study cohort included 150 patients who underwent 164 cycles. A total of 127 cycles were included. Of them, 64 were treated with GnRH-a and 63 with progesterone.

Hypothesis: This RCT suggests that GnRH-a for luteal phase support is associated with a higher positive β-hCG pregnancy rate and clinical pregnancy rate, compared with standard progesterone support in an antagonist-based protocol triggered with hCG, while maintaining a similar safety profile.


Eligibility criteria: Inclusion Criteria:Criteria for inclusion were patients aged between 18-45 years, BMI between 19-35, infertility diagnosis of male factor, tubal factor, anovulation, unexplained and age-related. Patients with or without infertility diagnosis, who underwent IVF for PGT were also included.

-

Exclusion Criteria:

Exclusion criteria were triggering with agents other than hCG, previous 3 or more failed cycles in which a good quality embryo or embryos were transferred, endometriosis, hydrosalpinx, hypogonadotropic hypogonadism, and Mullerian malformations. Drop-out criteria included no fresh embryo transfer, intolerance to GnRH-a, and nasal congestion during the luteal phase.

-

Primary outcomes:
measure: pregnancy
timeFrame: 2 weeks
Secondary outcomes:
measure: clinical pregnancy
timeFrame: 5 weeks
measure: ovarian hyperstimulation syndrome
timeFrame: 5 weeks
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek medical Center
Study officials:
References:
Clinical trial NCT06944093: Listen to a Audio Book
Official title: Noninvasive Mechanical Ventilation is Applied to Patients With Hypercapnic Respiratory Failure on the Agitation Scores and Respiratory Parameters
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Failure With Hypercapnia
Lead sponsor: Ataturk University
Sponsor class: OTHER
First posted: 2025-04-25
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study investigates how listening to audiobooks affects agitation scores and respiratory parameters (like breathing rate, depth, and oxygen saturation) in patients receiving non-invasive mechanical ventilation (NIMV) for hypercapnic respiratory failure in an intensive care unit. Participants will listen to an audiobook of their choice during their 2-hour NIMV treatment. Their agitation levels and respiratory parameters will be measured before, during, and after NIMV application. The goal is to evaluate whether audiobooks can reduce patient agitation and improve respiratory outcomes, offering a low-cost, easy-to-use, and effective approach for better patient care.


Eligibility criteria: Inclusion Criteria:

Patients aged 18 years or older Patients hospitalized in the Chest Diseases Intensive Care Unit Diagnosed with Hypercapnic Respiratory Failure Undergoing Non-invasive Mechanical Ventilation (NIMV) No hearing impairment Conscious and alert patients

Exclusion Criteria:

Patients unwilling to participate or wishing to withdraw from the study

Primary outcomes:
measure: Agitation Scores
timeFrame: 10 month
measure: Breathing Rate
timeFrame: 10 month
measure: Breathing Depth
timeFrame: 10 month
measure: SpO₂ Levels
timeFrame: 10 month
Secondary outcomes:
Other outcomes:
Locations:
city: Erzurum
country: Turkey
facility: Atatürk University Faculty of Nursing
Study officials:
References:
Clinical trial NCT04028193: Fat Supplementation on Dumping Syndrome Associated Symptoms
Official title: The Effect of Fat Supplementation on the Appearance of Symptoms Associated With Dumping Syndrome in Patients Undergone Bariatric Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dumping Syndrome
Keywords: Dumping syndrome
Fat supplement
post bariatric surgery
Lead sponsor: Technological Educational Institute of Thessaly
Sponsor class: OTHER
First posted: 2019-07-22
Enrollment: 25
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of the study is the investigation of the effect of fat supplement on gastric emptying rate and the appearance of symptoms of Dumping Syndrome in patients who have undergone gastrointestinal- duodenal surgery. Patients who have undergone bariatric surgery have been examined for the presence of the Dumping syndrome, with glucose measurements, the Sigstad's questionnaire and questionnaire of Arts. Patients diagnosed positive, reiterated the examination process in a second meeting consuming an extra fat supplement. The data obtained on the different appointments were compared between the two groups in a cross over design.


Eligibility criteria: Inclusion Criteria:

* Patients with Dumping Syndrome

Exclusion Criteria:

* Patients with diabetes mellitus type 1 and 2, Patients with impaired balance of fluids and electrolytes, Patients on diuretics pills or corticosteroids or hypoglycemic tablets and Insulin.

Primary outcomes:
measure: Glucose Levels
timeFrame: before the ingestion of the carbohydrate and fat supplement (baseline)
measure: Glucose Levels
timeFrame: 30 minutes after the ingestion of the carbohydrate and fat supplement
measure: Glucose Levels
timeFrame: 60 minutes after the ingestion of the the carbohydrate and fat supplement
measure: Glucose Levels
timeFrame: 90 minutes after the ingestion of the the carbohydrate and fat supplement
measure: Glucose Levels
timeFrame: 120 minutes after the ingestion of the the carbohydrate and fat supplement
measure: Sigstad's Questionnaire
timeFrame: 1st hour after the ingestion of the supplements
measure: Sigstad's Questionnaire
timeFrame: 2nd hour after the ingestion of the supplements
measure: Arts's Questionnaire
timeFrame: 1st hour after the ingestion of the supplements
measure: Arts's Questionnaire
timeFrame: 2nd hour after the ingestion of the supplements
Secondary outcomes:
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Nikoleta Chatzipapa
Study officials:
References:
Clinical trial NCT01152593: Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Surgical Wound Infection
Cesarean Section
Staphylococcus Aureus
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-06-29
Enrollment: 400
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The investigators believe that irradication of nose colonization of staphyloccocus aureus will reduce the incidence of surgical site infections after cesarean section.


Eligibility criteria: Inclusion Criteria:

* Women assigned to undergo cesarean section

Exclusion Criteria:

* All others

Primary outcomes:
measure: Reduction of the incidence of surgical site infections after cesarean section
timeFrame: Four years
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT00441493: Fluvastatin Versus Hepatitis C Virus
Official title: A Dose Finding Study of Fluvastatin for in Vivo Demonstration of Inhibiting Hepatitis C Replication in Patients Infected With Chronic Hepatitis C With Special Attention to the African-American Population.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatitis C
Keywords: Hepatitis C
fluvastatin
Lead sponsor: Bader, Ted, M.D.
Sponsor class: INDIV
Collaborators: name: US Department of Veterans Affairs
First posted: 2007-03-01
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a dose finding and efficacy trial for fluvastatin versus hepatitis C.

Detailed description: Four different oral doses of fluvastatin will be used for 14 days and the viral load of hepatitis C will be measured weekly. This has been extended to different doses for 9-12 weeks.

Eligibility criteria: Inclusion Criteria:

* HCV RNA positive

Exclusion Criteria:

* Testing positive for alcohol or marijuana

Primary outcomes:
measure: Viral Load Reduction, Liver test changes
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: VA Medical Center
state: Oklahoma
Study officials:
affiliation: VA Medical Center and University of Oklahoma
name: Ted Bader, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01935193: Aspirin Resistance Reversibility in Diabetic Patients
Official title: Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Aspirin Resistance
Keywords: platelets aggregation
asa resistance
Lead sponsor: Azienda Ospedaliera San Giovanni Battista
Sponsor class: OTHER
First posted: 2013-09-05
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is assessing the prevalence of aspirin resistance in a cohort of diabetic patients. Those found resistant has been undergone pharmacological tests using different drug formulations to investigate the reversibility of aspirin resistance.


Eligibility criteria: Inclusion Criteria:

* diabete mellitus type 2
* asa since 30 days at least
* plts \>150000 and \<450000

Exclusion Criteria:

* recent ACS (within 30 days)
* anticoagulant therapy
* haemorragic diathesis

Primary outcomes:
measure: platelets aggregation assessed by two tests (PFA100 and VerifyNow)
timeFrame: 24 hours
Secondary outcomes:
measure: stability of aggregation state after the reversion of aspirin resistance using oral formulation of lysine acetylsalicylate
timeFrame: 1 month
Other outcomes:
Locations:
city: Torino
country: Italy
facility: San Giovanni Battista Hospital
Study officials:
References:
Clinical trial NCT03193671: Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis
Official title: Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ovarian Neoplasms
Diagnoses Disease
Biomarkers
Algorithms
Keywords: HE4
CA125
RMI
ROMA
Lead sponsor: Göteborg University
Sponsor class: OTHER
First posted: 2017-06-21
Enrollment: 684
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed with a cyst/tumor in the pelvis already enrolled for surgery. Included at 6 different Hospitals.

Brief summary: This study evaluates the biomarkers CA125 and HE4 and the algorithms RMI and ROMA on a normal population in the western region of Sweden. The aim is to improve diagnosis of ovarian cancer.

If the investigators observe a clear improvement in the early diagnosis of EOC, the investigators aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of Sweden.

Detailed description: The investigators are currently using CA125 and RMI in diagnosing patients with a pelvic cyst/tumor and referring them to tertiary centers for surgery in the western region of Sweden. The diagnostic accuracy is unsatisfying why the investigators are evaluating HE4 and ROMA as a complement, in combination or separately to improve diagnostic accuracy.

The trial is based on a normal population cohort of patients included at all the hospitals in the region. The patients were included before surgery and the biomarkers analysed on serum samples withdrawn preoperatively.

If the investigators observe a clear improvement in the early diagnosis of EOC, the investigators aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of Sweden.

Eligibility criteria: Inclusion Criteria:

* 18 years of age, understand spoken and written Swedish information, admitted for surgery for a cyst/tumos in the pelvis

Exclusion Criteria:

* Rejected participation, cytotoxic chemotherapy prior to surgery, rejected surgery, serum sample failure, already included at another hospital

Primary outcomes:
measure: Can the investigators improve diagnostic accuracy in women diagnosed with a cyst/tumor in the pelvis
timeFrame: 12 months
Secondary outcomes:
measure: Improve triage of patients to tertiary centers for surgery
timeFrame: 12 months
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Gothenburg University, Sahlgrenska University Hospital
Study officials:
References:
citation: Lycke M, Ulfenborg B, Malchau Lauesgaard J, Kristjansdottir B, Sundfeldt K. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Clin Chem Lab Med. 2021 Aug 13;59(12):1954-1962. doi: 10.1515/cclm-2021-0510. Print 2021 Nov 25.
Clinical trial NCT03097393: Serum Procalcitonin Level May Predict Acute Kidney Injury in ICU Patients With Sepsis
Official title: Serum Procalcitonin Level May Predict Acute Kidney Injury in ICU Patients With Sepsis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Kidney Injury
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2017-03-31
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ICU patients with sepsis

Brief summary: The aim of this study is to examine if procalcitonin (PCT) can be used for early prediction of AKI septic patients in ICU.

Detailed description: 67 patients with sepsis were enrolled in this study. On admission, PCT was measured together with serum creatinine, urea, and other inflammatory markers. Quick Sepsis-related Organ Failure Assessment was calculated at the emergency department. Patients were classified into those with Acute kidney injury (AKI) and non-AKI groups.

Eligibility criteria: Inclusion Criteria:

* ICU patients with sepsis

Exclusion Criteria:

* Patient known to have End-stage kidney disease
* Patients on Renal replacement therapy
* patients without procalcitonin level within 24 hours from admission.

Primary outcomes:
measure: development of AKI
timeFrame: 28 Days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01411371: Catheter Ablation Versus Medical Treatment of AF in Heart Failure
Official title: Catheter Ablation Versus Medical Treatment of AF in Heart Failure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Atrial Fibrillation
Heart Failure
Keywords: Atrial fibrillation
Heart failure
Catheter ablation
Lead sponsor: Barts & The London NHS Trust
Sponsor class: OTHER
Collaborators: name: British Heart Foundation
First posted: 2011-08-08
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Heart failure and atrial fibrillation (AF) often coexist, and each increases the morbidity and mortality associated with the other. The investigators hypothesized that restoration of normal sinus rhythm by catheter ablation is superior to medical treatment of AF in heart failure. This study randomizes patients with heart failure and persistent AF to medical treatment of AF or catheter ablation to restore sinus rhythm.


Eligibility criteria: Inclusion Criteria:

* Persistent atrial fibrillation
* Symptomatic heart failure

Exclusion Criteria:

* Reversible causes of heart failure
* Contraindications to catheter ablation

Primary outcomes:
measure: Difference in ejection fraction between groups
timeFrame: 6 months
Secondary outcomes:
measure: Difference in peak VO2 between groups
timeFrame: 6 months
measure: Difference in NYHA class between groups
timeFrame: 6 months
measure: Difference in BNP between groups
timeFrame: 6 months
measure: Difference in Quality of Life between groups
timeFrame: 6 months
measure: Reduction in end systolic volume
timeFrame: 6 months compared to baseline
measure: Difference in heart failure symptoms
timeFrame: 6 months
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Barts & The London NHS Trust
state: UK
Study officials:
affiliation: Professor of Cardiology, Barts & The London NHS Trust
name: Richard J Schilling, MD FRCP
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney V, Duncan E, Page SP, Ullah W, Unsworth B, Mayet J, Dhinoja M, Earley MJ, Sporton S, Schilling RJ. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014 Feb;7(1):31-8. doi: 10.1161/CIRCEP.113.000806. Epub 2014 Jan 1.
Clinical trial NCT03855293: Protecting the Corneal Endothelium During Cataract Surgery Using the Anterior Capsule
Official title: Protecting the Corneal Endothelium During Cataract Surgery Using the Anterior Capsule: a Prospective Randomised Double-masked Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endothelial Cell Loss, Corneal
Lead sponsor: Vienna Institute for Research in Ocular Surgery
Sponsor class: OTHER
First posted: 2019-02-26
Enrollment: 70
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cataract surgery is one of the most frequently performed surgical procedures worldwide. Since the introduction of phacoemulsification to remove the cataractous lens, risk and complication rates of cataract surgery decreased significantly.

The phacoemulsification technique utilizes a high-intensity ultrasound energy for the fragmentation and emulsification of the lens. One of the main complications during phacoemulsification, is damaging of the endothelium due to contact with lens fragments of the nucleus following turbulent flow of irrigating solution, resulting in corneal damage, inflammation of the endothelium and corneal edema.

In this study we want to evaluate the effect of the anterior capsule, gained by capsular rhexis, as a corneal shield during phacoemulsification on the corneal endothelium.


Eligibility criteria: Inclusion Criteria:

* Cataract
* Age 21 and older
* Written informed consent prior to surgery
* Moderate to severe nuclear or mixed cataract

Exclusion Criteria:

* Corneal pathologies
* Pregnancy
* Patients with an increased surgical risk (i.e. patients with pseudoexfoliation syndrome, patients with the potential risk of intra-operative floppy iris syndrome)

Primary outcomes:
measure: endothelium cell loss
timeFrame: 1 year
Secondary outcomes:
measure: central corneal thickness
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References: